Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis

dc.creatorMendonca, JA
dc.creatorMarques-Neto, JF
dc.creatorSamara, AM
dc.creatorAppenzeller, S
dc.date2012
dc.dateMAR
dc.date2014-07-30T14:33:10Z
dc.date2015-11-26T16:58:51Z
dc.date2014-07-30T14:33:10Z
dc.date2015-11-26T16:58:51Z
dc.date.accessioned2018-03-28T23:46:29Z
dc.date.available2018-03-28T23:46:29Z
dc.identifierRheumatology International. Springer Heidelberg, v. 32, n. 3, n. 815, n. 818, 2012.
dc.identifier0172-8172
dc.identifierWOS:000301044100041
dc.identifier10.1007/s00296-011-1812-3
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/60023
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/60023
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1278038
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionTargeted inhibition of tumor necrosis factor-alpha (TNF-alpha) is an effective therapy in rheumatoid arthritis (RA). In some rare cases, autoimmune phenomena, including drug-induced lupus and vasculitis, is described. However, the immunological mechanisms underlying the development of autoimmunity are unknown. We report 3 patients that developed autoimmune phenomena while in use of TNF-alpha inhibitor, showing concomitant increase in rheumatoid factor (RF). We hypothesize that the increase in RF several months prior to the occurrence of vasculitis may help identifying other patients at risk for the development of vasculitis secondary to these medications.
dc.description32
dc.description3
dc.description815
dc.description818
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionFAPESP [2008/02917-0, 2009/06049-6]
dc.descriptionCNPq [300447/2009-4]
dc.languageen
dc.publisherSpringer Heidelberg
dc.publisherHeidelberg
dc.publisherAlemanha
dc.relationRheumatology International
dc.relationRheumatol. Int.
dc.rightsfechado
dc.rightshttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.sourceWeb of Science
dc.subjectRheumatoid factor
dc.subjectVasculitis
dc.subjectRheumatoid arthritis
dc.subjectTNF-alpha inhibitors
dc.subjectCutaneous Vasculitis
dc.subjectTherapy
dc.subjectEtanercept
dc.titleIncreased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución